Januvia diabetes drug molecule

Januvia diabetes drug molecule

A624/0438 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 75.1MB

Downloadable file size: 711.6KB

Price image Pricing

Please login to use the price calculator


Caption: Januvia diabetes drug, molecular model. Januvia (sitagliptin) is a hypoglycaemic drug, one that reduces blood sugar levels. Diabetes is a condition in which blood sugar levels can get dangerously high due to a lack of insulin, the hormone that reduces them. Januvia works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP- 4). DPP-4 rapidly deactivates the incretin hormone GLP-1 (glucagon-like peptide 1), which promotes insulin release. Hence, inhibiting DPP-4 prolongs the effects of GLP-1, keeping insulin levels high. Atoms are colour-coded: carbon (grey), hydrogen (yellow), oxygen (red), nitrogen (blue) and fluorine (green). Januvia is marketed by Merck, and was approved in the USA in October 2006.

Release details: Model release not required. Property release not required.

Keywords: anti-diabetic, anti-hyperglycaemic, ball and stick, biochemical, biochemistry, biological, biology, blood sugar, chemical, chemistry, compound, compounds, diabetes, diabetic, dipeptidyl peptidase-4, dpp-4 inhibitor, drug, enzyme inhibitor, glp-1, glucagon-like peptide 1, glucose, high blood sugar, hyperglycaemia, hypoglycaemic, incretin, inhibition, inhibitor, januvia, medical, medication, medicine, merck, molecular, molecular model, molecule, one, oral, pharmaceutical, pharmaceutics, pharmacological, pharmacology, single, sitagliptin

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.